Bines, et al. Human. New England Journal of Medicine. 2018
In healthy term neonates, is oral human rotavirus vaccine administered on a neonatal schedule or infant schedule more effective than placebo at preventing rotavirus gastroenteritis until age 18 months?
Design: A randomised, double-blind, parallel group, placebo-controlled trial. Oral human rotavirus vaccine (RV3-BB) was administered on a neonatal schedule (0–5 days, 8 weeks, and 14 weeks of age), or an infant schedule (8 weeks, 14 weeks, and 18 weeks of age), or as a placebo.
The administration of a human neonatal rotavirus vaccine (RV3-BB), via a neonatal or infant vaccine schedule, is efficacious in preventing severe gastroenteritis until 18 months of age in children in Indonesia.